ThromboGenics Launches JETREA® in United States for Non-Surgical Treatment of Vitreomacular Adhesion

February 6, 2013

On January 14, 2012, ThromboGenics NV (Euronext Brussels: THR), a Belgian biopharmaceutical company, commenced the sale of JETREA® (ocriplasmin) in the United States for non-surgical treatment of symptomatic vitreomacular adhesion (VMA).

In October 2012, the FDA had approved JETREA® in the US as the first pharmacological agent for the treatment of symptomatic VMA upon the earlier recommendation of one of its panels.

VMA is a condition where the vitreous gel (jelly in the center of the eye) starts to move away from the macula (the part of the retina responsible for reading vision) resulting in subsequent loss or distortion of vision due to tugging on the macula. JETREA is an enzyme that breaks down proteins in the eye responsible for VMA.

Prior to the launch of JETREA the standard of care for treating VMA was pars plana vitrectomy (PPV), which involves surgically removing the vitreous from the eye.

Retina specialists in the United States have begun announcing the availability of JETREA as a non-surgical treatment option for VMA.

Click here to read ThromboGenics’ release announcing the U.S. launch.

The therapy is likely to be available in Europe shortly from Alcon (a division of Novartis) upon the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for use of JETREA.




Jump down to form below to submit your own comments

Comments are closed.